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OutcomesIntroduction: Neoadjuvant systemic therapy (NST) has several potential advantages in the treatment of
breast cancer. However, there is currently considerable variation in NST use across the UK. The NeST
study is a national, prospective, multicentre cohort study that will investigate current patterns of care
with respect to NST in the UK.
Methods and analysis: Phase 1 – a national practice questionnaire (NPQ) to survey current practice.
Phase 2 – a multi-centre prospective cohort study of breast cancer patients, undergoing NST.
Women undergoing NST as their MDT recommended primary breast cancer treatment between
December 2017 and May 2018 will be included. The breast surgery and oncological professional associ-
ations and the trainee research collaborative networks will encourage participation by all breast cancer
centres.
Patient demographics, radiological, oncological, surgical and pathological data will be collected, includ-
ing complications and the need for further intervention/treatment. Data will be collated to establish cur-
rent practice in the UK, regarding NST usage and variability of access and provision of these therapies.
Prospective data on 600 patients from ~50 centres are anticipated.
Trial registration: ISRCTN11160072.
Ethics and dissemination: Research ethics approval is not required for this study, as per the online Health
Research Authority decision tool. The information obtained will provide valuable insights to help patients
make informed decisions about their treatment. These data should establish current practice in the UK
concerning NST, inform future service delivery as well as identifying further research questions.
6 G.W. Irwin et al. / International Journal of Surgery Protocols 18 (2019) 5–11This protocol will be disseminated through the Mammary Fold Academic Research Collaborative
(MFAC), the Reconstructive Surgery Trials Network and the Association of Breast Surgery. Participating
units will have access to their own data and collective results will be presented at relevant conferences
and published in appropriate peer-reviewed journals, as well as being made accessible to relevant patient
groups.
 2019 The Authors. Published by Elsevier Ltd on behalf of Surgical Associates Ltd. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Breast cancer affects 54,000 women per year in the United King-
dom (UK) [1], and treatment comprises a combination of loco-
regional therapies (surgery and radiotherapy) as well as systemic
treatments (chemotherapy, endocrine and biological therapies).
Selection of systemic therapies is made at an individual patient
level, based on tumour biology, clinicopathological variables and
patient fitness and preference.
Randomised trials have shown that systemic chemotherapy is
equally effective in both the neoadjuvant and adjuvant settings,
in terms of overall and distant disease-free survival [2,3]. However,
the prescription of systemic therapies in the neoadjuvant setting
may have some specific advantages over their adjuvant use.
Neoadjuvant therapy facilitates in vivo assessment of tumours’
sensitivity to specific treatments. Attaining a pathological com-
plete response (pCR) following neoadjuvant treatment is an excel-
lent prognostic indicator at an individual patient level [4].
Pathological complete response rates vary according to breast can-
cer subtype, and may be as high as 60% in the HER2 positive sub-
group [5–7]. Where pCR, is not achieved patients at high risk of
relapse may be stratified to additional adjuvant treatments to
improve their outcome. Neoadjuvant therapy (NST) may also
downsize primary cancers in order to facilitate breast-conserving
surgery, where a mastectomy would otherwise have been
required. This is an attractive option for many patients who wish
to preserve their breast. Notably however a recent meta-analysis
demonstrated that the modest gains in breast conservation with
the use of NST, are associated with higher local recurrence rates,
although this reflects historical patient data who received subopti-
mal local therapy when compared to today’s standards [8].
Neoadjuvant endocrine therapy has also been utilised in oestro-
gen receptor (ER) positive breast cancer [9]. Indeed, some studies
have suggested that in strongly hormone receptor positive disease,
it may be as effective as chemotherapy. In current practice neoad-
juvant endocrine therapy tends to be reserved for older, less fit
patients [10,11].
There are limited data about the utilization of NST throughout
the UK. A recent study in the Netherlands found wide variance in
NST use, with rates ranging from 0-97% in different centres [12].
The UKMastectomy Decisions Audit (MasDA) highlighted inconsis-
tencies in the utilisation of neoadjuvant treatment across the UK
[13]. Many patients with large ER positive or HER2 positive
tumours, who were potentially candidates for NST and were likely
to benefit most from downstaging, proceeded directly to mastec-
tomy without being offered NST.
Where NST takes place, increasing pCR rates have not been
matched by increasing rates of breast conservation [14,15]. One
issue is a lack of consensus in surgical approach to excising the
tumour footprint in the breast and axilla, and indeed, whether or
not surgery is required at all following apparent complete
response. This is an area of ongoing research [16]. Furthermore,
there is variation in surgical practice with respect to the timing
of SLNB in relation to neoadjuvant therapy, with some centres per-
forming pre-treatment SLNB, and others tailoring axillary treat-
ment to the post-neoadjuvant clinical and radiological picture[17]. There is also substantial variation in methods for reporting
response to NST, both in terms of radiological monitoring of
response during treatment and assessing clinical response [18].
Finally, the lack of consistency in reporting of pathological treat-
ment response makes the interpretation of clinical trial outcomes
and the planning of further treatment or future research difficult
given much variability [19].
Therefore, there appears to be considerable variation in the uti-
lization of NST across the UK. There is a need to explore current UK
practice through a large-scale, multicentre prospective cohort
study, and to use the data generated to define best practice.
Although there are challenges in undertaking such a large-scale,
prospective, multicentre cohort study, the trainee research collab-
orative model has emerged as both a time- and cost-efficient
method for delivering high-quality prospective audit and research
[20,21]. These have a proven track record in prospective cohort
studies [22–24], and more recently, this model has been applied
successfully in the field of breast surgery through the iBRA and
MasDA studies [13,25–27]. The NeST (Neoadjuvant Systemic Ther-
apy in breast cancer) study aims to work with the Northern Ireland
Surgical Research Collaborative, the Mammary Fold Academic and
Research Collaborative and existing networks of enthusiastic
breast surgery trainees and MDT consultants to deliver a robust
assessment of current practice and a high-quality prospective audit
of practice and outcomes of NST across the UK.
2. Methods and analysis
2.1. Primary aim
The aim of NeST is to work with the trainee collaborative net-
work to elucidate current practice of NST in breast cancer in the UK.
Specific objectives will be
1. To establish current stated practice regarding the use of NST
across the UK
2. To determine the current practice of NST including
 Indications for use
 Treatment modalities in common use
 Monitoring of response to treatment
 Pathological reporting of response to NST
3. To document surgical decision-making in the context of NST
with respect to both the breast and axilla
4. To determine the use of further adjuvant therapies (radio-
therapy and systemic therapies) following NST
5. To determine pathological response rates to NST in routine
clinical practice
6. To establish best practice with regards to the use of NST,
with a view to generating national guidelines
The study aims and objectives are summarised in Table 1.
2.2. Study design
The NeST study consists of two parts:
Table 2
Inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
Age > 16 years Patients entering ‘‘window of
opportunity” clinical trials
Histologically confirmed diagnosis of
breast cancer
MDT recommended treatment of
neoadjuvant systemic therapy
Table 1
Study objectives and endpoints
Endpoint Outcome measure
Primary endpoints To investigate variation in use of neoadjuvant systemic
therapies in the UK
 Percentage of patients being treated with neoadjuvant
chemotherapy and endocrine therapy
 Percentage of patients in each tumour molecular subtype
To assess surgical practice following neoadjuvant therapy  Percentage of patients having mastectomy/breast conserving
surgery
Determine pathological response rates after neoadjuvant
therapy
 Pathological complete response rate (as a percentage of all
treated patients) to neoadjuvant therapy
Secondary endpoints Explore the stated indications for the use of neoadjuvant
systemic therapy in current UK practice
 Indications given by multidisciplinary team for choice of
treatment
Examine treatment regimens in common use  Prescribed treatment regimens for neoadjuvant therapy
Investigate how response to neoadjuvant therapy is
monitored and reported across the UK
 Number of patients having imaging (and which imaging
modality) during therapy
Investigate surgical management of the axilla following
neoadjuvant therapy
 Percentage of patients having sentinel lymph node biopsy and
axillary node clearance before and after neoadjuvant therapy
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Phase 1 aims to document current stated practice with respect
to the use of NST in the UK, and will be delivered via a National
Practice Questionnaire (NPQ), applied to all participating MDTs.
The NPQ will be developed by members of the steering group. It
will assess stated indications for NST, surgical management of
the breast and axilla post-NST and systems for monitoring and
reporting responses to treatment. The NPQ will be piloted in 2–3
centres and iteratively modified based on feedback to ensure com-
pleteness and ease of use.
All breast cancer multidisciplinary teams will be invited to par-
ticipate in the NPQ phase. A trainee lead at each centre will be
identified and will be asked to complete the questionnaire with
input from all MDT members.
2.2.2. Phase 2 – multi-centre prospective cohort study of patients
treated with neoadjuvant systemic therapy
The aim of Phase 2 is to document the actual practice and out-
comes of NST of breast cancer in the UK.
All surgical and oncological units treating patients with breast
cancer in the UK will be eligible to participate. Units will be invited
by email to participate through the Mammary Fold (MF) Breast
Trainees’ Association, the Association of Breast Surgery, the Associ-
ation of Surgeons in Training, the National Trainee Research Col-
laborative (NTRC), the Breast Cancer Trainees Research
Collaborative Group, the NCRI Breast Clinical Studies Group (CSG)
and the Reconstructive Surgery Trials Network (RSTN). These pro-
fessional associations have endorsed the study and will encourage
units to participate and support their trainees in recruiting patients
and collecting data.
Participating centres will recruit consecutive patients recom-
mended to receive NST into the study. Potential participants will
be identified prospectively by the local study team via clinics, local
MDT meetings, consultant surgeons and clinical nurse specialists
Inclusion/exclusion criteria are summarised in Table 2.
Simple demographics, procedure and process data will be col-
lected for each participant. Data will be recorded in an anonymised
format using a unique alphanumeric study identification number
on a secure web-based database (REDCap) designed by Vanderbilt
University to support data capture for research studies [28,29]. The
database has been designed using advanced logic, such that only
data fields relevant to the treatment modality used (e.g.
chemotherapy or endocrine therapy) will appear in the data cap-
ture forms. This will minimize the burden of data collection and
entry for collaborators, optimizing data quality within the study.
Data regarding treatment, clinical/radiological response and
surgical outcomes will be collected prospectively. Indications for
NST will be classified, in priority order where possible, as primary
and secondary. The required data fields for the prospective studyare shown summarised in the protocol appendices (Supplementary
data files). For the purpose of this study, pCR will be defined as ‘no
residual invasive disease in either breast or axillary lymph nodes’
as this has been shown to have the strongest correlation with
event-free and overall survival [31]. Clinical and radiological
response will be described using modified RECIST criteria [30] as
shown in Table 3.
Pathological response data will be obtained from the formal his-
tological report from local pathology department. Similarly, radio-
logical response details will be obtained from reports of breast
imaging by radiologists, clinical response frommedical notes/ elec-
tronic patient record and details of systemic treatment from
notes/electronic patient record/ electronic chemotherapy or drug
prescribing systems. Data will also be collected on patients for
whom neoadjuvant systemic therapy was recommended by the
local MDT but declined by the patient, including reasons for declin-
ing treatment.2.2.2.1. Data validation and management. For quality assurance pur-
poses, the consultant principal investigator at selected sites will
nominate an independent individual to validate a percentage of
submitted data. Approximately 5% of submitted datasets will be
independently validated. Independent assessors will be required
to confirm the reliability of data by examining MDT meeting
records, theatre logbooks and operating diaries and computer sys-
tems to ensure that appropriate cases have been accurately
recorded. If concordance between independent assessors and sub-
mitted data is <90%, data from that unit will not be included in the
analysis. Only datasets with >90% data completeness will be
included in the final analysis. This is similar to quality assurance
measures utilised in projects of a similar nature [31].
Data collection will adhere to Caldicott II principles [32]. Data
for each patient will be anonymised with a unique alpha-
numeric code. No patient identifiable data will be stored or
recorded centrally for the purposes of this study. Anonymised data
only will be uploaded to the REDCap database. Patient identifiers
will be stored locally at each participating hospital following local
institutional approval, and will be held in line with the institution’s
Table 4
Study timelines.
Sep – Nov 2017 Pilot study questionnaires
Sep – Dec 2017 Registration of interest from breast units
Sep – Dec 2017 Local approval from participating units
Oct 2017 – March 2018 National Practice Questionnaire
Completion
1 Dec 2017 – 30 November 2018 Patient recruitment to prospective audit
with pre-operative MDT discussion inside
these dates
1 Dec 2017 – 31 Dec 2019 Data collection period to allow time for
completion of neoadjuvant therapy and
surgery
31 December 2019 Closing date for data submission
1 May  30 October 2019 Data Analysis – National Practice
Questionnaire
1 Jan 2020 – 1 Apr 2020 Data validation and analysis – Prospective
audit data
October 2019 – January 2020 Write up and dissemination – National
Practice Questionnaire
May – July 2020 Write up and dissemination – Prospective
Audit data
Amendment chronology.
There have been no substantial amendments to the study protocol.
Table 3
Modified RECIST response criteria.
Complete Response No evidence of residual disease on clinical
examination
or standard routine imaging
Partial Response Reduction in maximum tumour diameter on clinical
examination or routine imaging
Stable Disease No change in tumour size on examination or imaging
Disease Progression Increase in the maximum tumour diameter on
examination
or using imaging
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supervising consultant named on the institutional approval, ensur-
ing continuity of custodianship of the data.
If long-term data are required, proportional ethical approval will
be sought centrally by the NeST team to facilitate the central collec-
tion of the locally maintained spreadsheets linking study ID to NHS
number from participating centres. Only centres with appropriate
ethical approval will be able to contribute data at this stage.
2.2.2.2. Anticipated recruitment and sample size. There is a lack of
detailed data regarding indications for NST utilisation. Although
the UK Systemic Anti-Cancer Therapy Database holds some data
in respect of NST use, it does not currently collect the level of detail
that will be captured in the NeST study [33]. Themajority of the 144
breast units within the UK are likely to consider this treatment for
their patients, although it is anticipated that therewill be significant
variation across the country. Based on a 60% participation rate, it
would be anticipated that 100 units may contribute to the study.
The study team will approach breast units via both trainees and
the professional associations to maximise participation. Based on
previous experience with prospective collaborative studies in
breast cancer such as iBRA, it is anticipated that closer to 40% of
UK breast units may choose to participate in this audit [25]. From
our pilot, we estimate accrual of between 2 and 5 patients per
month per unit; with 40 centres participating, we would therefore
anticipate a recruitment of around 720 patients over a 6month per-
iod (3 patients per month, from 40 centres, for 6 months). However,
the study will aim to engage as many UK units as possible. Conse-
quently, and in order to obtain a representative picture of current
UKpractice,we estimate that itwill be necessary to run the prospec-
tive audit for a minimum period of 6 months from 1/12/17 until
30/11/18, or at least 600 patients have been registered.
2.2.2.3. Statistical analysis. The study report will be prepared
according to the STROBE (Strengthening the Reporting of Observa-
tional Studies in Epidemiology) reporting guidelines for observa-
tional studies [34]. All data analysis will occur centrally by the
NeST Study Steering Group, with support from Medical Statisti-
cians within the Centre for Public Health at Queen’s University
Belfast.
Simple summary statistics will be calculated to describe demo-
graphic, procedure, process and outcome data overall and at a site
level. Categorical data will be summarised by counts and percent-
ages. Continuous data will be summarised by mean, standard devi-
ation and range if data are normally distributed. Median,
interquartile range and range will be reported if the data is skewed.
No formal statistical testing is planned. Study timelines are sum-
marized in Table 4.
2.2.2.4. Patient and public involvement. Patients have been involved
since the inception of this study, and are represented on the NeST
Study Steering Group (MG, as a representative of the Northern Ire-
land Cancer Research Consumer Forum), and there has been
patient input into the development of the study protocol and thedata collection instruments. Patient involvement will remain key
to data analysis and dissemination as the study continues.3. Discussion
Use of NST in breast cancer clearly has potential advantages for
patients, allowing an increase in the use of breast conserving sur-
gery, and giving accurate information regarding tumour response
to treatment. This approach has recently been the subject of some
controversy, with some commentators suggesting that the use of
neoadjuvant therapy be reconsidered [34].
There remains lack of consensus around optimal patient selec-
tion for NST, and around the monitoring and reporting of treatment
response. The NeST Study is therefore important in improving our
understanding of current patterns of care in this situation. This
study will generate much needed novel data, concerning rates of
access to and utility of NST in breast cancer, facilitate the design
of appropriate randomised controlled trials and may inform best
practice, allowing the development of appropriate national
guidelines.
In addition, the study will strengthen the existing research col-
laborative network in breast surgery, created through the iBRA
study, and establish new collaborative networks in medical and
clinical oncology, radiology and pathology. This will allow the
development of multidisciplinary research networks to support
future collaborative projects in breast cancer.
The potential challenges for this project warrant consideration.
The proposed datasets are complex and there is potential for
incomplete data. In order to minimise this, the datasets have been
piloted prior to study initiation to ensure they are not cumbersome
and to streamline the flow through the online data capture sheets.
This also allows the removal of any redundant or ambiguous ques-
tions. In addition, REDCap allows the use of logic to ensure that
only the appropriate fields relevant to the procedure or indication
are displayed during data capture.
There is the possibility that participation will be biased towards
the most motivated centres, and that this may not provide a truly
representative picture of practice nationwide. To address this, we
would seek in future to combine NeST data with additional infor-
mation from linkage to routinely collected NHS national datasets
such as the Systemic Anti-Cancer Therapy Dataset (www.chemo-
dataset.nhs.uk) to give a wider picture of UK practice. Furthermore,
the NeST Study does not plan to capture information on all cancers
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meaning that absolute rates of NST usage cannot be calculated. It is
accepted that this is a limitation of this study, but determining
rates of usage of NST is not the primary aim of NeST.
Finally, although the project will allow the collection of valu-
able data around treatment access and selection, surgical decision
making and short-term outcomes, it will not provide any informa-
tion regarding the long-term outcomes of NST in these patients. If
long-term data is required, proportional ethical approval will be
sought centrally by the NeST team to facilitate the central collec-
tion of the locally maintained spreadsheets linking study ID to
NHS number from participating centres. Only centres with appro-
priate ethical approval will be able to contribute data at this stage.4. Ethics and dissemination
The proposed study will not affect clinical care. Research ethics
approval is not required and has been confirmed by the Health
Research Authority online decision tool (http://www.hra-decision-
tools.org.uk/research/). A Trainee Lead will be identified at each
participating unit, who will in turn identify a named supervising
consultant to act as the principal investigator for registration pur-
poses. The study lead, in consultation with the principal investiga-
tor, will be required to register the audit and obtain local audit
approvals for study participation prior to commencing patient
recruitment. A copy of local approval will be forwarded to the NeST
study team. Patient consent is not required, as no patient identifi-
able data are being recorded and there is no risk to patients.
If long-term data are required, proportional ethical approval
will be sought centrally by the NeST team to facilitate the central
collection of the locally maintained spreadsheets linking study ID
to NHS number from participating centres. Only centres with
appropriate ethical approval will be able to contribute data at this
stage.
This protocol will be disseminated through the Mammary Fold
Academic Research Collaborative (MFAC), the Reconstructive Sur-
gery Trials Network, the Association of Breast Surgery, the British
Association of Plastic, Reconstructive and Aesthetic Surgeons and
others. Participating units will have access to their own data and
information from individual units will be fed back with a compar-
ison to the national data. National results will be fed back to the
appropriate professional associations. Collective results will be
analysed and the results presented at relevant scientific meetings
and published in appropriate peer-reviewed journals. Results will
also be made available to relevant patient advocacy groups such
as Independent Cancer Patients’ Voice. Thus, results will be avail-
able to aid in the decision-making for women considering NST.5. Research registration unique identifying number (UIN)
1. Name of the registry: ISRCTN
2. Unique Identifying number or registration ID: ISRCTN11160072
3. Hyperlink to the registration (must be publicly accessible):
https://www.isrctn.com/ISRCTN11160072?q=&filters=condi-
tionCategory:Cancer&sort=&offset=2&totalResults=2133&
page=1&pageSize=10&searchType=basic-search
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Trial registration data:Data category InformationPrimary registry and trial
identification numberISRCTN11160072Date of registration in primary
registry10th June 2019Sources of monetary or material
supportSupported by a grant from the Association of Breast SurgerySponsor Queen’s University of Belfast (for subsequent study phases requiring sponsorship)
researchgovernance@qub.ac.ukContact for public queries SMcI (s.mcintosh@qub.ac.uk)(continued on next page)
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Public title A study to help understand the outcomes of pre-surgical treatment for breast cancer
Scientific title NeST: Neoadjuvant systemic therapy in breast cancer. A national prospective multicentre audit of
neoadjuvant systemic therapy in breast cancer
Countries of recruitment United Kingdom
Interventions No interventions – anonymised data collection only
Key inclusion criteria Age > 16 years
Histologically confirmed diagnosis of breast cancer
MDT recommended treatment of neoadjuvant systemic therapyKey exclusion criteria Patients entering ‘‘window of opportunity” clinical trials
Study type Prospective cohort study
Observational
Date of first enrolment December 2017
Recruitment status Data collection ongoing
Primary outcomes Investigate variation in practice in the use of neoadjuvant systemic therapy in the UK
Assess surgical practice following neoadjuvant therapy
Determine pathological response rates after neoadjuvant therapyKey secondary outcomes Explored stated indications for use of neoadjuvant systemic therapy
Examine treatment regimens in common use
Investigate how response to neoadjuvant treatment is assessed/reported across the UKInvestigate
surgical management of the axilla following neoadjuvant therapyAppendix B. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.isjp.2019.10.002.
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